ST 793

Drug Profile

ST 793

Alternative Names: TA 803

Latest Information Update: 06 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sigma-tau SpA
  • Developer Tanabe Seiyaku
  • Class Anti-ischaemics; Neuroprotectants; Nootropics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cerebral infarction; CNS disorders; Cognition disorders

Most Recent Events

  • 18 Apr 2002 Phase-II clinical trials in Cerebral infarction in Japan (PO)
  • 28 Jun 2001 No-Development-Reported for Cerebral infarction in Japan (PO)
  • 20 Dec 1997 Phase-II clinical trials for Cerebral infarction in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top